143,447 members

Skip to content. | Skip to navigation

News

NICE draft guidance for treating secondary progressive multiple sclerosis

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

NICE draft guidance for treating secondary progressive multiple sclerosis

NICE has issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).